Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Taysha Gene Therapies, Inc. (TSHA)

Taysha prices $200 million stock offering at $6.00 per share, closing expected June 26

Neutral Impact 4 of 5 financing Written later

Taysha Gene Therapies priced an underwritten public offering of common stock and pre-funded warrants, with the company expecting approximately $187.4 million in net proceeds, or approximately $215.6 million if underwriters fully exercise their option. The company says the proceeds, together with existing cash, will fund operations and capital expenditures into the second half of 2028, but the share count increase will dilute existing shareholders.

Key points

  • Sale of 32,500,001 common shares at $6.00 per share, plus pre-funded warrants for 833,333 shares at $5.999 each
  • Expected net proceeds of approximately $187.4 million; approximately $215.6 million if the underwriters' option for up to 5,000,000 additional shares is exercised in full
  • Closing expected on June 26, 2026, subject to customary closing conditions; company says cash runway extends into the second half of 2028

The filing

CompanyTaysha Gene Therapies, Inc. (TSHA)
Form8-K, current report
Filed with the SECJun 25, 2026, 4:26 PM ET
Accession number0001193125-26-282855

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.